Xtl Biopharmaceuticals Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
XTLB
- Investments
-
7
Xtl Biopharmaceuticals General Information
Description
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Contact Information
Website
www.xtlbio.comCorporate Office
- 5 Badner Street
- PO Box 8241
- Ramat Gan 5218102
- Israel
Corporate Office
- 5 Badner Street
- PO Box 8241
- Ramat Gan 5218102
- Israel
Xtl Biopharmaceuticals Timeline
Xtl Biopharmaceuticals Stock Performance
As of 19-Nov-2026, Xtl Biopharmaceuticals’s current market cap is $3.9M with 983M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.9M | 983M | 753K |
Xtl Biopharmaceuticals Financials Summary
As of 31-Dec-2025, Xtl Biopharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,472 | 6,472 | 14,109 | 3,095 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (812) | (812) | 433 | (1,823) |
| Net Income | (6,969) | (6,969) | (1,027) | (1,782) |
| Total Assets | 166 | 166 | 8,550 | 2,426 |
| Total Debt | 269 | 269 | 138 | 0 |
Xtl Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xtl Biopharmaceuticals Comparisons
Industry
Financing
Details
Xtl Biopharmaceuticals Competitors (21)
One of Xtl Biopharmaceuticals’s 21 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Savara | Formerly VC-backed | Yardley, PA | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Vicore Pharma Holding | Formerly VC-backed | Stockholm, Sweden | ||||
| Lilly USA | Corporation | Indianapolis, IN |
Xtl Biopharmaceuticals Patents
Xtl Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180043016-A1 | Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20200338195-A1 | Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20180043017-A1 | Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | Active | 22-Aug-2007 | ||
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | Inactive | 22-Aug-2007 | C07D215/36 |
Xtl Biopharmaceuticals Signals
Xtl Biopharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xtl Biopharmaceuticals Investments & Acquisitions (7)
Xtl Biopharmaceuticals’s most recent deal was a Merger/Acquisition with PsygaBio. The deal was made on 30-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PsygaBio | 30-Jun-2026 | Merger/Acquisition | Drug Discovery | ||
| NeuroNOS | 13-Jan-2026 | Merger/Acquisition | Drug Discovery | ||
| The Social Proxy | 14-Aug-2024 | Merger/Acquisition | Database Software | ||
| Geffen Residence & Renewal | 21-Nov-2012 | Secondary Transaction - Open Market | Drug Discovery | ||
| InterCure | 25-Jul-2012 | Merger/Acquisition | Pharmaceuticals |
Xtl Biopharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Xtl Biopharmaceuticals Exits (3)
Xtl Biopharmaceuticals’s most recent exit was on 14-Aug-2024 from The Social Proxy. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| The Social Proxy | 14-Aug-2024 | Completed |
|
||
| Geffen Residence & Renewal | 21-Nov-2012 | Completed |
|
||
| IviGene | 12-Mar-2001 | Corporate | Completed |
Xtl Biopharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| PsygaBio | Caesarea, Israel | 2021 | |
| InterCure | Herzliya, Israel | 1994 |
Xtl Biopharmaceuticals FAQs
-
When was Xtl Biopharmaceuticals founded?
Xtl Biopharmaceuticals was founded in 1993.
-
Where is Xtl Biopharmaceuticals headquartered?
Xtl Biopharmaceuticals is headquartered in Ramat Gan, Israel.
-
What is the size of Xtl Biopharmaceuticals?
Xtl Biopharmaceuticals has 5 total employees.
-
What industry is Xtl Biopharmaceuticals in?
Xtl Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Xtl Biopharmaceuticals a private or public company?
Xtl Biopharmaceuticals is a Public company.
-
What is Xtl Biopharmaceuticals’s stock symbol?
The ticker symbol for Xtl Biopharmaceuticals is XTLB.
-
What is the current market cap of Xtl Biopharmaceuticals?
The current market capitalization of Xtl Biopharmaceuticals is $3.9M.
-
Who are Xtl Biopharmaceuticals’s competitors?
Savara, Biocon, Novartis, Vicore Pharma Holding, and Lilly USA are some of the 21 competitors of Xtl Biopharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process